Results 241 to 250 of about 17,568,133 (310)

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Lancet, The, 2020
BACKGROUND Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer.
Javier Cortes, David W Cescon, Hope S Rugo   +2 more
exaly   +2 more sources

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

The Lancet, 2021
BACKGROUND This trial assessed the efficacy and safety of the GLP-1 analogue once a week subcutaneous semaglutide 2·4 mg versus semaglutide 1·0 mg (the dose approved for diabetes treatment) and placebo for weight management in adults with overweight or ...
M. Davies, L. Færch, O. Jeppesen, Arash Pakseresht, S. Pedersen, L. Perreault, J. Rosenstock, I. Shimomura, A. Viljoen, T. Wadden, I. Lingvay   +10 more
semanticscholar   +1 more source

Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet Respiratory Medicine, 2021
BACKGROUND Chronic rhinosinusitis with nasal polyps affects approximately 2-4% of the general population, and long-term use of systemic corticosteroids is associated with adverse effects.
Joseph K. Han, C. Bachert, W. Fokkens, M. Desrosiers, M. Wagenmann, Stella E. Lee, Steven G. Smith, N. Martin, B. Mayer, S. Yancey, A. Sousa, Robert H Chan, C. Hopkins   +12 more
semanticscholar   +1 more source

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.

The Lancet, 2021
BACKGROUND The global prevalence of ulcerative colitis is increasing, and induction and maintenance of remission is a crucial therapeutic goal. We assessed the efficacy and safety of filgotinib, a once-daily, oral Janus kinase 1 preferential inhibitor ...
B. Feagan, S. Danese, E. Loftus, S. Vermeire, S. Schreiber, T. Ritter, R. Fogel, R. Mehta, S. Nijhawan, R. Kempiński, R. Filip, I. Hospodarskyy, U. Seidler, F. Seibold, I. Beales, Hyo Jong Kim, J. McNally, C. Yun, Sally Zhao, Xiaopeng Liu, C. Hsueh, Chantal Tasset, R. Besuyen, Mamoru Watanabe, W. Sandborn, G. Rogler, T. Hibi, L. Peyrin-Biroulet   +27 more
semanticscholar   +1 more source

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

The Lancet Oncology, 2021
BACKGROUND Chemoradiotherapy is the standard of care for unresected locally advanced squamous cell carcinoma of the head and neck. We aimed to assess if addition of avelumab (anti-PD-L1) to chemoradiotherapy could improve treatment outcomes for this ...
N. Lee, R. Ferris, A. Psyrri, R. Haddad, M. Tahara, J. Bourhis, K. Harrington, P. Chang, Jin-Ching Lin, M. Razaq, M. M. Teixeira, J. Lövey, J. Chamois, A. Rueda, Chaosu Hu, L. Dunn, M. Dvorkin, Steven De Beukelaer, D. Pavlov, H. Thurm, Ezra E. W. Cohen   +20 more
semanticscholar   +1 more source

Placebo controlled trials

BMJ, 2014
Researchers assessed the efficacy of varenicline (a licensed cigarette smoking cessation aid) in helping users of smokeless tobacco to quit. A double blind placebo controlled parallel group randomised controlled trial study design was used. The intervention was varenicline 1 mg twice daily. Treatment was delivered for 12 weeks, with 14 weeks’ follow-up
Philip, Sedgwick, Carwyn, Hoope
openaire   +2 more sources

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

The Lancet Oncology, 2020
BACKGROUND CLEOPATRA was a phase 3 study comparing the efficacy and safety of pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with HER2-positive metastatic breast cancer.
S. Swain, D. Miles, Sung-Bae Kim, Y. Im, S. Im, V. Semiglazov, E. Ciruelos, A. Schneeweiss, S. Loi, E. Monturus, E. Clark, A. Knott, E. Restuccia, M. Benyunes, J. Cortés   +14 more
semanticscholar   +1 more source

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.

The Lancet Respiratory Medicine, 2020
BACKGROUND At present, no approved pharmacotherapies are available for unclassifiable interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung.
T. Maher, T. Corte, A. Fischer, M. Kreuter, D. Lederer, M. Molina-Molina, J. Axmann, K. Kirchgaessler, K. Samara, F. Gilberg, V. Cottin   +10 more
semanticscholar   +1 more source

Questioning Placebo Controls

Science, 2000
In his News of the Week article examining the ethical issue of placebo control groups in psychiatric drug trials (21 Apr., p. [416][1]), Martin Enserink suggests that nobody would consider using placebos for such treatable diseases as cancer and AIDS. However, this is not true.
openaire   +2 more sources